![Lars Gredsted](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lars Gredsted
Director/Miembro de la Junta en Varmx BV .
Cargos activos de Lars Gredsted
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Wellcome Trust Technology Transfer
![]() Wellcome Trust Technology Transfer Investment ManagersFinance Wellcome Trust Technology Transfer (Wellcome Trust Technology Transfer) is a venture capital subsidiary of The Wellcome Trust Ltd. founded in 1992 by Graham Eric Fagg. The firm is headquartered in London. | Analista de Capital Privado | 01/01/2012 | - |
Enterome SA
![]() Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Director/Miembro de la Junta | 01/01/2021 | - |
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Director/Miembro de la Junta | - | - |
Historial de carrera de Lars Gredsted
Antiguos cargos conocidos de Lars Gredsted.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Canbex Therapeutics Ltd.
![]() Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | - | 10/11/2017 |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Director/Miembro de la Junta | - | - |
Formación de Lars Gredsted.
University of Cambridge | Doctorate Degree |
University of Copenhagen | Graduate Degree |
Estadísticas
Internacional
Reino Unido | 4 |
Dinamarca | 3 |
Francia | 2 |
Operativa
Director/Board Member | 4 |
Graduate Degree | 2 |
Private Equity Analyst | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Wellcome Trust Technology Transfer
![]() Wellcome Trust Technology Transfer Investment ManagersFinance Wellcome Trust Technology Transfer (Wellcome Trust Technology Transfer) is a venture capital subsidiary of The Wellcome Trust Ltd. founded in 1992 by Graham Eric Fagg. The firm is headquartered in London. | Finance |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Canbex Therapeutics Ltd.
![]() Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Health Technology |
Enterome SA
![]() Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
- Bolsa de valores
- Insiders
- Lars Gredsted
- Experiencia